EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Redrawing the Map in Prurigo Nodularis: From Conventional Approaches to Targeted Biologics

Göknur Kalkan

Dermatologic Therapy · 2026-01 · 2026 (1)

DOI: 10.1155/dth/1342428 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 12.08.2026. Verfasst von Göknur Kalkan. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prurigo nodularis (PN) is a chronic, neuroimmune‐mediated dermatosis characterized by intense pruritus and nodular lesions that severely impair patient quality of life. The limitations of conventional therapies in providing more than symptomatic relief have necessitated novel approaches targeting the disease’s heterogeneous pathogenesis.

Objective

This review evaluates current treatment algorithms and the potential future clinical frameworks tailored to the immunological and neuropathic endotypes of PN.

Methods

A comprehensive literature search was conducted across PubMed/MEDLINE, Scopus, and Google Scholar databases for English‐language peer‐reviewed articles, clinical trials, and guidelines published up to December 2025, focusing on targeted and conventional therapies for prurigo nodularis.

Results

In addition to approved biologics such as the IL‐4/IL‐13 pathway inhibitor dupilumab and the IL‐31 receptor antagonist nemolizumab, this review discusses emerging options, including JAK inhibitors, mast cell–targeted therapies, and opioid modulators. Current evidence suggests that these targeted agents offer significant improvements in both pruritus and lesion resolution by addressing specific molecular drivers.

Conclusion

The management of PN is entering a transitional phase, with an emerging goal to evolve from uniform approaches toward future biomarker‐ and phenotype‐based, disease‐modifying, and personalized strategies. Defining these endotypes more precisely will be essential for optimizing potential therapeutic individualization and long‐term clinical success.

Zitieren

APA

Kalkan, G. (2026). Redrawing the Map in Prurigo Nodularis: From Conventional Approaches to Targeted Biologics. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/1342428

Vancouver

Kalkan G. Redrawing the Map in Prurigo Nodularis: From Conventional Approaches to Targeted Biologics. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/1342428

BibTeX
@article{Kalkan2026,
  author = {Kalkan, Göknur},
  title = {Redrawing the Map in Prurigo Nodularis: From Conventional Approaches to Targeted Biologics},
  journal = {Dermatologic Therapy},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/dth/1342428}
}
Kostenlos starten →